Soligenix announced that its drug candidate SGX945 (dusquetide) has received Promising Innovative Medicine designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the treatment of Behcet's Disease. This designation represents the first step toward potential inclusion in the U.K.'s Early Access to Medicines Scheme, which allows patients with life-threatening or seriously debilitating conditions to access promising therapies earlier than standard regulatory pathways would permit.
The PIM designation was granted based on Phase 2 clinical data indicating that dusquetide may provide a significant advantage over existing treatments while demonstrating a favorable potential benefit-risk profile for patients with this rare inflammatory disorder. Behcet's Disease is a chronic condition characterized by inflammation of blood vessels throughout the body, leading to symptoms including mouth sores, skin lesions, and eye inflammation that can progress to vision loss if untreated.
For patients with rare diseases like Behcet's, the Early Access to Medicines Scheme represents a crucial pathway to potentially life-changing treatments. The program allows for earlier availability of medicines that have demonstrated promising clinical data but have not yet received full marketing authorization. This can be particularly significant for conditions where current treatment options are limited or inadequate.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's Specialized BioTherapeutics business segment is developing dusquetide as part of its first-in-class innate defense regulator technology platform. Beyond Behcet's Disease, the company is also developing dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.
The company's broader pipeline includes HyBryte (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy for cutaneous T-cell lymphoma, with regulatory approvals being sought worldwide following successful completion of the second Phase 3 study. Development programs also include expansion of synthetic hypericin (SGX302) into psoriasis treatment. Additional information about the company's development programs is available through their corporate communications at https://ibn.fm/SNGX.
In the Public Health Solutions business segment, Soligenix maintains development programs for RiVax, a ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola, and CiVax, a vaccine candidate for the prevention of COVID-19. These programs incorporate the company's proprietary heat stabilization platform technology, ThermoVax, and have been supported with government grant and contract funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
The PIM designation for SGX945 represents a significant milestone in the development pathway for this potential treatment. For the rare disease community, regulatory designations that facilitate earlier access to promising therapies can substantially impact patient outcomes and quality of life. The designation also validates the clinical data generated to date and supports continued development of dusquetide across inflammatory conditions. As with all investigational therapies, further clinical development and regulatory review will determine the ultimate availability and labeling of SGX945 for Behcet's Disease patients.
